SRZN - Surrozen Inc

https://www.surrozen.com

Momentum: Bearish

Recent News

Bullish

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 week, 3 days ago • score: 0.22

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule ...

Neutral

Surrozen to Present at Upcoming Healthcare Investor Conference

GlobeNewswire • 1 week, 4 days ago • score: 0.07

Surrozen to Present at H.C. Wainwright 27th Annual Global Investment Conference ...

Neutral

Surrozen to Present at Upcoming Healthcare Investor Conference

GlobeNewswire • 2 weeks, 3 days ago • score: 0.07

Surrozen management will present at the Cantor Global Healthcare Conference 2025 on Thursday, September ...

Bullish

Surrozen Reports Q2 Profit on Gains

Motley Fool • 1 month ago • score: 0.21

Surrozen ( NASDAQ:SRZN ) , a biotechnology company focused on Wnt pathway modulation in regenerative medicine, delivered its second quarter 2025 earnings on August 8, 2025. The most notable headline was the shift from last year's deep loss to reported net income of $39.7 million ( GAAP ) for Q2 ...

Neutral

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire • 1 month ago • score: 0.13

Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit

Neutral

Surrozen to Present at Upcoming Healthcare Investor Conference

GlobeNewswire • 1 month, 1 week ago • score: 0.09

Surrozen to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August ...

Neutral

Surrozen to Present at Upcoming Healthcare Investor Conference - Surrozen ( NASDAQ:SRZN )

Benzinga • 1 month, 1 week ago • score: 0.09

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Surrozen, Inc. ( "Surrozen" or the "Company" ) SRZN, a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today ...

Bullish

Down -29.72% in 4 Weeks, Here's Why Surrozen ( SRZN ) Looks Ripe for a Turnaround

Zacks Commentary • 3 months, 4 weeks ago • score: 0.18

Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Neutral

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

GlobeNewswire • 4 months ago • score: 0.12

Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway ...

Neutral

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire • 4 months ago • score: 0.05

Surrozen Reports First Quarter 2025 Financial Results and Business Update ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$18.17

52W Low

$5.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.62

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.71

EV/Revenue (<3 favorable)

1.72

P/S (TTM) (<3 favorable)

8.28

P/B (<3 favorable)

2.22

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.09%

Institutions (25–75% balanced)

71.27%

Shares Outstanding

8,570,400

Float

4,798,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

12,621,000

Gross Profit (TTM)

-8,468,000

EPS (TTM)

-7.82

Profit Margin (>10% good)

-1.32%

Operating Margin (TTM) (higher better)

-9.17%

ROE (TTM) (>15% strong)

-0.63%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.4347

0.4897

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025